IL253971B - Method of purifying albumin-fusion proteins - Google Patents
Method of purifying albumin-fusion proteinsInfo
- Publication number
- IL253971B IL253971B IL253971A IL25397117A IL253971B IL 253971 B IL253971 B IL 253971B IL 253971 A IL253971 A IL 253971A IL 25397117 A IL25397117 A IL 25397117A IL 253971 B IL253971 B IL 253971B
- Authority
- IL
- Israel
- Prior art keywords
- fusion proteins
- purifying albumin
- albumin
- purifying
- fusion
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562132198P | 2015-03-12 | 2015-03-12 | |
| PCT/US2016/022003 WO2016145307A1 (en) | 2015-03-12 | 2016-03-11 | Method of purifying albumin-fusion proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL253971A0 IL253971A0 (en) | 2017-10-31 |
| IL253971B true IL253971B (en) | 2021-10-31 |
Family
ID=56878920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL253971A IL253971B (en) | 2015-03-12 | 2017-08-14 | Method of purifying albumin-fusion proteins |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10683340B2 (https=) |
| EP (2) | EP3842451A1 (https=) |
| JP (3) | JP6862348B2 (https=) |
| KR (2) | KR20170124592A (https=) |
| CN (1) | CN107428817B (https=) |
| AU (4) | AU2016228806B2 (https=) |
| CA (2) | CA2977675A1 (https=) |
| ES (1) | ES2839211T3 (https=) |
| IL (1) | IL253971B (https=) |
| WO (1) | WO2016145307A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012323316B2 (en) | 2011-10-11 | 2017-08-10 | Viela Bio, Inc. | CD40L-specific Tn3-derived scaffolds and methods of use thereof |
| MX2020004151A (es) | 2017-10-30 | 2020-08-13 | Takeda Pharmaceuticals Co | Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos. |
| CA3115341A1 (en) | 2018-05-16 | 2019-11-21 | Lib Therapeutics, Llc | Compositions comprising pcsk9-binding molecules and methods of use |
| BR112021008797A2 (pt) * | 2018-11-09 | 2021-08-31 | Neopep Pharma Gmbh & Co. Kg | Polipeptídeos para o tratamento de síndromes de estresse, imunorreação e derrame |
| EP3711772A1 (en) * | 2019-03-20 | 2020-09-23 | Oslo Universitetssykehus HF | Recombinant proteins and fusion proteins |
| CN110295152A (zh) * | 2019-07-29 | 2019-10-01 | 北京泓恩生物科技有限公司 | 一种重组产朊假丝酵母尿酸酶的纯化方法 |
| US11180540B2 (en) * | 2019-12-06 | 2021-11-23 | Regeneron Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
| JP2023525034A (ja) | 2020-05-08 | 2023-06-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法 |
| CN115996940A (zh) * | 2020-07-01 | 2023-04-21 | 免疫医疗有限责任公司 | 用于纯化生物治疗剂的洗涤剂和方法 |
| CN112062833A (zh) * | 2020-10-09 | 2020-12-11 | 国药集团武汉血液制品有限公司 | 一种从血浆组分ⅳ沉淀中提取人血白蛋白的方法 |
| CN115677848A (zh) * | 2022-10-24 | 2023-02-03 | 通化安睿特生物制药股份有限公司 | 一种制备高纯度高稳定性蛋白质的方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030022308A1 (en) * | 1992-01-31 | 2003-01-30 | Aventis Behring L.L.C. | Fusion polypeptides of human serum albumin and a therapeutically active polypeptide |
| US20120149873A1 (en) * | 2009-05-07 | 2012-06-14 | Novozymes Biopharma Dk A/S | Method for purifying albumin |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001007657A1 (en) | 1999-07-27 | 2001-02-01 | Phylos, Inc. | Peptide acceptor ligation methods |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| ES2078518T3 (es) | 1990-04-05 | 1995-12-16 | Roberto Crea | Mutagenesis por desplazamiento completo. |
| US7063943B1 (en) | 1990-07-10 | 2006-06-20 | Cambridge Antibody Technology | Methods for producing members of specific binding pairs |
| US5843701A (en) | 1990-08-02 | 1998-12-01 | Nexstar Pharmaceticals, Inc. | Systematic polypeptide evolution by reverse translation |
| US5866344A (en) | 1991-11-15 | 1999-02-02 | Board Of Regents, The University Of Texas System | Antibody selection methods using cell surface expressed libraries |
| US5440018A (en) * | 1992-05-20 | 1995-08-08 | The Green Cross Corporation | Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same |
| US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| DE69935248T2 (de) | 1998-12-02 | 2007-11-08 | Adnexus Therapeutics, Inc., Waltham | Dna-protein fusionen sowie anwendungen derselben |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7022479B2 (en) | 2000-01-24 | 2006-04-04 | Compound Therapeutics, Inc. | Sensitive, multiplexed diagnostic assays for protein analysis |
| US6951725B2 (en) | 2001-06-21 | 2005-10-04 | Compound Therapeutics, Inc. | In vitro protein interaction detection systems |
| KR100524872B1 (ko) | 2003-12-04 | 2005-11-01 | 씨제이 주식회사 | 인터페론 베타의 정제방법 |
| JP4939410B2 (ja) | 2004-07-06 | 2012-05-23 | バイオレン，インク． | 強化された特性を持つ変性ポリペプチドを発生させるためのルックスルー変異誘発 |
| EP1976876A4 (en) | 2005-12-22 | 2010-01-13 | Conjuchem Biotechnologies Inc | PROCESS FOR PRODUCING PREFORMED ALBUMIN CONJUGATES AND THERAPEUTIC AGENT |
| CN102014888A (zh) | 2007-07-03 | 2011-04-13 | 达努塔·克鲁谢夫斯卡 | α-酮戊二酸的新医药用途 |
| US20090176654A1 (en) | 2007-08-10 | 2009-07-09 | Protelix, Inc. | Universal fibronectin type III binding-domain libraries |
| EP2215246B1 (en) | 2007-10-31 | 2015-01-07 | MedImmune, LLC | Protein scaffolds |
| BRPI0919881B1 (pt) | 2008-10-31 | 2021-09-08 | Centocor Ortho Biotech Inc | Proteína de arcabouço e seu método de geração, biblioteca e seu método de construção, molécula de ácido nucleico, vetor de ácido nucleico, célula hospedeira, composição, dispositivo médico e artigo de fabricação |
| BRPI1008532B1 (pt) | 2009-02-12 | 2021-12-14 | Janssen Biotech, Inc | Arcabouço de proteína isolada, método para construção de uma biblioteca de arcabouço de proteína isolada, molécula de ácido nucleico isolada, vetor de ácido nucleico isolado, célula hospedeira de bactéria ou fungo, composição, dispositivo médico e artigo de manufatura para uso farmacêutico ou de diagnóstico em seres humanos |
| CA2776241A1 (en) | 2009-10-30 | 2011-05-05 | Novozymes Biopharma Dk A/S | Albumin variants |
| CA2789337A1 (en) | 2010-02-16 | 2011-08-25 | Medimmune, Llc | Hsa-related compositions and methods of use |
| CA2795325A1 (en) | 2010-04-13 | 2011-10-20 | Medimmune, Llc | Fibronectin type iii domain-based multimeric scaffolds |
| CN103379915A (zh) | 2011-02-15 | 2013-10-30 | 米迪缪尼有限公司 | Hsa相关组合物及使用方法 |
| AU2012323316B2 (en) * | 2011-10-11 | 2017-08-10 | Viela Bio, Inc. | CD40L-specific Tn3-derived scaffolds and methods of use thereof |
| MX2015005363A (es) * | 2012-11-08 | 2015-11-06 | Novozymes Biopharma Dk As | Variantes de albumina. |
-
2016
- 2016-03-11 EP EP20198757.5A patent/EP3842451A1/en active Pending
- 2016-03-11 JP JP2017548053A patent/JP6862348B2/ja active Active
- 2016-03-11 WO PCT/US2016/022003 patent/WO2016145307A1/en not_active Ceased
- 2016-03-11 CN CN201680014597.2A patent/CN107428817B/zh active Active
- 2016-03-11 ES ES16762595T patent/ES2839211T3/es active Active
- 2016-03-11 CA CA2977675A patent/CA2977675A1/en active Pending
- 2016-03-11 KR KR1020177028780A patent/KR20170124592A/ko not_active Ceased
- 2016-03-11 EP EP16762595.3A patent/EP3268389B1/en active Active
- 2016-03-11 US US15/557,358 patent/US10683340B2/en active Active
- 2016-03-11 KR KR1020247016329A patent/KR20240093725A/ko active Pending
- 2016-03-11 CA CA3260163A patent/CA3260163A1/en active Pending
- 2016-03-11 AU AU2016228806A patent/AU2016228806B2/en active Active
-
2017
- 2017-08-14 IL IL253971A patent/IL253971B/en unknown
-
2020
- 2020-06-15 US US16/901,812 patent/US11548933B2/en active Active
-
2021
- 2021-01-22 AU AU2021200423A patent/AU2021200423B2/en active Active
- 2021-03-31 JP JP2021061713A patent/JP7320550B2/ja active Active
-
2023
- 2023-01-06 US US18/150,983 patent/US20230340074A1/en active Pending
- 2023-05-16 JP JP2023080507A patent/JP7826243B2/ja active Active
- 2023-07-03 AU AU2023204271A patent/AU2023204271B2/en active Active
-
2026
- 2026-03-13 AU AU2026201911A patent/AU2026201911A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030022308A1 (en) * | 1992-01-31 | 2003-01-30 | Aventis Behring L.L.C. | Fusion polypeptides of human serum albumin and a therapeutically active polypeptide |
| US20120149873A1 (en) * | 2009-05-07 | 2012-06-14 | Novozymes Biopharma Dk A/S | Method for purifying albumin |
Non-Patent Citations (2)
| Title |
|---|
| BORNHORST, J. A., AND J. J. FALKE, PURIFICATION OF PROTEINS USING POLYHISTIDINE AFFINITY TAGS. APPLICATIONS OF CHIMERIC GENES AND HYBRID PROTEINS, PART A., 31 December 2000 (2000-12-31) * |
| BOYD D, KASCHAK T, YAN B., HIC RESOLUTION OF AN IGG1 WITH AN OXIDIZED TRP IN A COMPLEMENTARITY DETERMINING REGION, 15 April 2011 (2011-04-15) * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016145307A1 (en) | 2016-09-15 |
| IL253971A0 (en) | 2017-10-31 |
| AU2021200423A1 (en) | 2021-02-25 |
| JP2023103368A (ja) | 2023-07-26 |
| CN107428817B (zh) | 2022-07-12 |
| AU2023204271A1 (en) | 2023-07-27 |
| JP2018513124A (ja) | 2018-05-24 |
| CN107428817A (zh) | 2017-12-01 |
| KR20240093725A (ko) | 2024-06-24 |
| AU2026201911A1 (en) | 2026-04-02 |
| AU2016228806B2 (en) | 2020-10-22 |
| AU2016228806A1 (en) | 2017-08-31 |
| US20180105575A1 (en) | 2018-04-19 |
| JP7826243B2 (ja) | 2026-03-09 |
| CA2977675A1 (en) | 2016-09-15 |
| JP7320550B2 (ja) | 2023-08-03 |
| JP2021105025A (ja) | 2021-07-26 |
| US20230340074A1 (en) | 2023-10-26 |
| EP3268389A4 (en) | 2018-08-08 |
| AU2023204271B2 (en) | 2026-04-02 |
| BR112017019401A2 (pt) | 2018-05-02 |
| JP6862348B2 (ja) | 2021-04-21 |
| ES2839211T3 (es) | 2021-07-05 |
| CA3260163A1 (en) | 2026-03-02 |
| KR20170124592A (ko) | 2017-11-10 |
| EP3268389A1 (en) | 2018-01-17 |
| EP3268389B1 (en) | 2020-09-30 |
| US11548933B2 (en) | 2023-01-10 |
| EP3842451A1 (en) | 2021-06-30 |
| AU2021200423B2 (en) | 2023-04-06 |
| US20200407423A1 (en) | 2020-12-31 |
| US10683340B2 (en) | 2020-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL253971B (en) | Method of purifying albumin-fusion proteins | |
| IL261404A (en) | Improved differentiation method | |
| IL254516B (en) | Proteins specific for cd137 | |
| EP3342545A4 (en) | ROBOT SYSTEM | |
| IL265016B (en) | Methods for purifying antibodies | |
| DK3292141T3 (da) | Fusionsproteiner | |
| EP3368250A4 (en) | ROBOTIC COOPERATIVE SYSTEM | |
| IL285146A (en) | Methods of purifying fc-containing proteins | |
| EP3289414A4 (en) | IMPROVED STEREOLITHOGRAPHIC SYSTEM | |
| DK3191809T3 (da) | System og fremgangsmåde til fremstilling af en farmaceutisk forbindelse | |
| DK3730511T3 (da) | Proteinoprensning | |
| IL254883A0 (en) | A method for protein purification | |
| IL272807A (en) | A method for cleaning proteins | |
| DK3147369T3 (da) | Fremgangsmåde til produktion af fibroinlignende protein | |
| EP3345729A4 (en) | ROBOT SYSTEM | |
| IL261560B (en) | Method for protein purification | |
| FI20155672A7 (fi) | Menetelmä uusiutuvan propaanin erottamiseksi ja puhdistamiseksi | |
| IL250232A0 (en) | Method of processing unhardened concrete | |
| DK3237433T3 (da) | Fremgangsmåde til fremstilling af protein | |
| DK3253743T3 (da) | Syntetisk fremgangsmåde til fremstilling af 2-furansyre-derivater | |
| FI20145326A7 (fi) | Menetelmä nosturin kääntöajamiseksi | |
| IL247996B (en) | Method for detecting protein modifications | |
| HUE051265T2 (hu) | Eljárás dimetil-szulfoxid tisztítására | |
| IL254638B (en) | Method for determining tactical actions | |
| DK3233885T3 (da) | Fremgangsmåde til koncentrering af proteiner |